Catalent Reports Fourth Quarter And Fiscal Year 2016 Results
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the fourth quarter and fiscal year 2016, which ended June 30, 2016.
Fourth quarter 2016 revenue of $532.2 million increased 4% as reported and increased 6% in constant currency from $510.1 million reported in the fourth quarter a year ago. For the fiscal year 2016, revenue was $1.85 billion, an increase of 1% as reported and an increase of 6% in constant currency. All three of the Company’s reporting segments posted constant currency revenue growth for the fourth quarter and the fiscal year, led by a double-digit increase in the Clinical Supply Services segment for the fiscal year.
Fourth quarter 2016 revenue of $532.2 million increased 4% as reported and increased 6% in constant currency from $510.1 million reported in the fourth quarter a year ago. For the fiscal year 2016, revenue was $1.85 billion, an increase of 1% as reported and an increase of 6% in constant currency. All three of the Company’s reporting segments posted constant currency revenue growth for the fourth quarter and the fiscal year, led by a double-digit increase in the Clinical Supply Services segment for the fiscal year.